The development of simple tests to predict a leukaemic relapse in young patients is a step closer thanks to researchers from the Sainte-Justine University Hospital Research Center and the University of Montreal. Approximately 20 percent of young leukaemia patients who are treated with stem cells derived from umbilical cord blood will experience leukaemic relapse. The researchers' findings, published recently in Blood, demonstrate that the blame falls partially on a subset of white blood cells called "T cells." Until now, this process had been poorly understood.

"We have shown that a particular marker on the T-cells, PD-1, was found significantly more frequently in those young patients in whom relapses were about to occur," says lead author, Dr. Hugo Soudeyns, an investigator at the Sainte-Justine University Hospital Research Center, affiliated with Université de Montreal. "PD-1 is also an indicator of 'T cell exhaustion', a process whereby T cells lose their capacity to multiply and are less effective at fighting viruses and cancer cells."

Dr. Soudeyns and his colleagues analyzed blood samples from young children who received an umbilical cord blood transplant for the treatment of blood disorders, including leukaemia. They were particularly interested in studying the three to six month time period post-transplantation, when the children were most susceptible to both relapse and infection. During this time, expression of the PD-1 marker peaked, suggesting that many of these T cells were at the end of their life cycle and thus less effective.

“Our findings suggest that measurement of exhaustion markers such as PD-1 could serve as an early predictor of leukaemic relapse – a very serious complication,” says Dr. Soudeyns. “Our next step is to repeat these experiments in larger groups of patients.”

Thanks to the financial support of the Fondation Centre de cancérologie Charles-Bruneau, Dr Soudeyns’ team was able to count on a new ELISpot reader, which analyzes the reaction of cells to stimulus. This reader played an important part in the study of blood samples selected for this test. The Fondation is proud of its positive contribution to this research and congratulates Dr Soudeyns for this remarquable scientific breakthrough.

Leukaemia is a type of blood cancer. Children with leukaemia are frequently treated with chemotherapy and radiation to eradicate the cancer cells, but this treatment also leads to the destruction of both their red and white blood cells. To replenish these cells, leukaemic children often undergo a bone marrow transplant. Another similar procedure involves transplantation of umbilical cord blood instead of bone marrow.

Source: University of Montreal